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ABSTRACT
Aberrant levels of circulating microRNAs are potential biomarkers for the early 
detection of colorectal cancer. The aim of this study was to study miR-139-3p and miR-
622 in serum as a non-invasive biomarker for colorectal cancer diagnosis. We applied 
quantitative polymerase chain reaction to determine the levels of miR-139-3p and 
miR-622 in 42 pairs of tumor and adjacent non-tumor tissues, and in serum samples 
of 117 patients and 90 control subjects. Our results showed that miR-139-3p was 
silenced whereas miR-622 was overexpressed in colorectal cancer. Similarly, serum 
miR-139-3p level was significantly lower in colorectal cancer patients than in control 
subjects whereas miR-622 was more frequently detectable in patients. ROC analysis 
showed that AUC of miR-139-3p was 0.9935, with a sensitivity of 96.6% and specificity 
of 97.8%. Serum miR-139-3p level showed high sensitivity and specificity for both 
early and late stage CRCs and proximal and distal CRCs. Detectable serum miR-622 
showed a sensitivity of 87.5% and specificity of 63.5% for discriminating CRC patients, 
but the sensitivity dropped for late stage patients (72.7%). We also included analyses 
of the blood CEA level for comparing the diagnostic performance of these blood-based 
biomarkers. The median level in CRC patients (3.6 ng/ml) was significantly higher 
than that in control (1.8 ng/ml). The AUC value of CEA in diagnosing CRC patients was 
0.7515. CEA showed a positive correlation with tumor stage and age of patients and 
its level was higher in male. Collectively, serum miR-139-3p has strong potential as 
a promising non-invasive biomarker in colorectal cancer detection.
INTRODUCTION
Worldwide colorectal cancer (CRC) is the third most 
common cancer in men and the second in women. It is a 
leading cause of cancer related deaths and results in over 
600 000 deaths annually [1–3]. Patient survival is highly 
dependent on the tumor stage at the time of diagnosis. 
The 5-year survival rate of CRC patients decreased from 
90% for localized disease to 70% and 13% for regional 
and distant diseases, respectively [4], suggesting that 
the mortality rate can be greatly reduced if the patients 
can be diagnosed at earlier stage. However, due to the 
asymptomatic nature of CRC at early stages, less than 
40% of CRC patients are diagnosed at localized stage [4]. 
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Therefore, a reliable, economic and non-invasive approach 
is urgently in need to provide screening to patients at risk 
in order to improve the prognosis of patients with CRC.
MicroRNAs (miRNAs) are small non-coding RNA 
sequences of 19-25 nucleotides which function as post-
transcriptional regulators of gene expression [5]. Many 
miRNAs which mediate cell growth and tumor progression 
have been found to be dysregulated in CRC [6]. Some of 
these dysregulated miRNAs are secreted into blood and can 
be detected in serum or plasma in highly stable form, hence 
circulating miRNAs have emerged as potential blood-based 
biomarkers for human cancers [7–9].
In this study, we investigated the levels of miR-
139-3p and miR-622 in serum samples of CRC patients 
and control subjects, and evaluated their potential as non-
invasive biomarkers for CRC screening.
RESULTS
Dysregulation of miR-139-3p and miR-622 in 
CRC tissues
The expression levels of miR-139-3p and miR-622 
were determined in 42 paired tumor and adjacent non-
tumor tissue. We found that miR-139-3p was significantly 
silenced in CRC tissues (P<0.001). Among the 33 
CRC patients who had miR-139-3p expression in their 
non-tumor tissues, only 2 of them showed detectable 
expression of this miRNA in their CRC samples (Figure 
1A). Moreover, the miR-139-3p level of these two 
CRC samples was significantly lower than their paired 
non-tumor tissues (−14.835 vs −11.688, P=0.031). 
By contrast, miR-622 was significantly induced in 
CRCs when compared with paired non-tumor tissues 
(Figure 1B, −11.248 vs −13.460, P<0.001). miR-622 
overexpression (at least 2-fold) was detected in 30 out of 
the 42 patients.
The correlation between miR-622 expression and 
patient's clinicopathological parameters was investigated. 
As indicated in Table 1, higher expression of miR-622 
level was associated with advanced stage (−10.605 vs 
−11.614, P=0.036), lymph node metastasis (−10.739 
vs −11.927, P=0.039) and distant metastasis (−10.461 
vs −11.686, P=0.039), and its expression positively 
correlated with tumor stage (R=0.375, P=0.0143). These 
results revealed that miR-622 expression prominently 
correlated with CRC progression. We did not investigate 
the clinicopathological significance of miR-139-3p in 
Figure 1: Expression of miR-139-3p and miR-622 in CRC tissue and serum samples. (A) Number of CRCs and non-tumor 
tissues with detectable miR-139-3p level; p<0.001 (fisher exact test). (B) Relative miR-622 expression in 42 paired CRC and adjacent non-
tumor tissues; p<0.001 (paired t-test). (C) Relative miR-139-3p expression in control subjects (N=90) and CRC patients (N=117); p<0.001 
(Student’s t-test). (D) Percentage of control subjects and CRC patients with detectable serum miR-622 level; p<0.001 (fisher exact test).
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CRC as its expression level was undetectable in most 
CRC tissues. Nonetheless, the significant dysregulation of 
miR-139-3p, and miR-622 as well, in CRC indicated their 
potentials as biomarkers for CRC.
Serum levels of miR-139-3p and miR-622 in 
CRC patients and control subjects
To investigate the potential of miR-139-3p and 
miR-622 as non-invasive biomarkers, the serum levels of 
miR-139-3p and miR-622 were detected in CRC patients 
and control subjects. As shown in Figure 1C, the serum 
miR-139-3p level in CRC patients was −6.500, which 
was significantly lower than that of the control subjects 
(-0.628, P<0.001). By contrast, we found that serum miR-
622 was more frequently detected in CRC patients than 
in normal subjects (Figure 1D). It was detected in only 
32.5% of normal subjects, but was detected in 87.8% of 
CRC patients (P<0.001).
Evaluation of serum miR-139-3p and miR-622 as 
potential biomarkers of CRC
Receiver operating characteristic (ROC) curve was 
plotted to evaluate the diagnostic accuracy of serum miR-
139-3p. As shown in Figure 2A, miR-139-3p could well 
discriminate CRC patients from control subjects with area 
under the curve (AUC) value of 0.9935 (95%CI=0.9868-
1.000, P<0.0001). The sensitivity and specificity at cutoff 
value of −3.524 were 96.6% and 97.8%, respectively, 
which met the 90/90 standard for cancer biomarkers [10]. 
The positive and negative predictive values were 98.3% 
and 93.6%, respectively. These statistics suggested that 
serum miR-139-3p had a high discriminating power to 
distinguish CRC patients from control subjects.
We also studied the diagnostic potential of serum 
miR-622. In the last section we showed that miR-622 
was more frequently detected in serum samples of CRC 
patients when compared with normal subjects, hence we 
investigated whether detectable level of serum miR-622 
indicated a higher risk of having CRC. The sensitivity and 
specificity of detectable serum miR-622 for diagnosing 
CRC were 87.8% and 67.5%, respectively. The positive 
and negative predictive values were 73.5% and 84.4%, 
respectively. These findings indicated that serum miR-622 
was not accurate enough for CRC diagnosis.
Diagnostic performance of serum miR-139-3p 
and miR-622 for CRC patients with tumors of 
different stages and locations
As shown in Figure 2B, there was no statistically 
significant difference in serum miR-139-3p level between 
early and late stage CRCs (−6.804 versus −6.633, 
P=0.441). ROC curves were plotted to evaluate the 
ability of serum miR-139-3p to screen early stage and late 
stage patients from controls. The AUCs in early and late 
stage CRC patients were 0.9949 and 0.9914, respectively; 
sensitivities were 96.7% and 97.2%, and specificities 
were both 97.8%, respectively. These findings suggested 
that serum miR-139-3p is a promising biomarker for 
both early and late stages of CRC. The performance of 
these potential diagnostic biomarkers was also compared 
between patients with CRCs at distal or proximal regions 
Table 1: Clinicopathological correlation of miR-622 expression in CRC patients
  Relative miR-622 expression in CRC tissue
−ΔCt (miR-622-RNU6)
p-value
Age <55 −11.562 0.421
 >=55 −11.074  
Gender Male −10.987 0.298
 Female −11.597  
Tumor Size <=5 −11.286 0.877
 >5 −11.193  
Lymph node metastasis Absent −10.739 0.039*
 Present −11.927  
Distant metastasis Absent −10.461 0.039*
 Present −11.686  
Tumor stage I to II −10.605 0.036*
 III to IV −11.614  
* indicates statistical significant difference between test parameters.
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(Figure 2C). There was no statistically significant 
difference in serum miR-139-3p level between patients 
with proximal CRC than those with distal CRC (−6.622 vs 
−6.215, P=0.291). The AUCs of miR-139-3p in distal and 
proximal CRCs patients 0.9944 and 0.9889, respectively. 
Their sensitivities were 97.4% and 92.3%, respectively, 
and specificities were both 97.78%, indicating that serum 
miR-139-3p is a promising biomarker for both early and 
late stages of CRC.
There was also no significant difference in serum 
miR-622 level between early and late stage CRCs (Figure 
2C, −6.693 versus −6.158, P=0.558); however, the 
sensitivities of serum miR-622 in diagnosing early and 
late stage CRCs were 90.0% and 72.7%, respectively, 
indicating that the diagnostic performance of serum miR-
622 level dropped in late stage CRC patients. There was 
no significant difference in serum miR-622 level between 
patients with proximal or distal CRCs (−6.290 versus 
−6.730, P=0.582). The sensitivities of serum miR-622 
for diagnosing CRCs at proximal and distal regions were 
similar (88.9% and 89.5%, respectively).
Furthermore, we examined whether these 
biomarkers were affected by demographic factors (age and 
gender). Serum miR-139-3p level showed no significant 
correlation with age and gender. Serum miR-622 level 
showed no correlation with gender, but its expression 
increased with age (R=0.511, P=0.003). The serum miR-
622 level in patients above 65 years old was ~2.5 fold of 
those below (−6.206 vs −7.543, P=0.045).
It has been suggested that blood carcino-embryonic 
antigen (CEA) level could serve as a biomarker for 
diagnosing CRC, hence we retrieved from our hospital’s 
Figure 2: Diagnostic performance of serum miR-139-3p for CRCs. (A) ROC curve was plotted to discriminate all CRC 
patients from control subjects. (B) Comparison of serum miR-139-3p level and diagnostic ability for early stage and late stage CRCs, and 
(C) proximal and distal CRCs.
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database the data of CEA level of the same serum samples 
for comparison on the diagnostic performance. The CEA 
level in CRC patients (median: 3.6 ng/ml) was significantly 
higher than that in control subjects (median: 1.8 ng/ml, 
p<0.001). Further evaluation on this potential biomarker 
showed that the AUC value of CEA in diagnosing CRC 
patients was 0.7515 (95%CI= 0.6864−0.8166, P<0.0001). 
The sensitivity and specificity at cutoff value of 2.5 ng/
ml were 65.2% and 71.0%, respectively; and 33.9% and 
96.8% at 5 ng/ml. The positive and negative predictive 
values at 2.5 ng/ml were 73.5% and 62.3%, respectively; 
and 90.9% and 54.3% at 5 ng/ml. The sensitivity decreased 
while the specificity increased for higher CEA cutoff value. 
Furthermore, the blood CEA level positively correlated 
with tumor stage (R=0.281, p=0.008). The sensitivities 
of CEA in diagnosing early stage and late stage CRC 
patients at 2.5 ng/ml were 54.7% and 77.8% and at 5 ng/
ml were 26.4% and 50%, respectively, indicating that CEA 
showed a higher sensitivity in patients with higher stage 
CRC. This finding is in line with previous reports that the 
sensitivity of CEA for early colon cancer patients is low 
and increases with an increasing stage of the disease [11, 
12]. Blood CEA level also correlated with age of overall 
population (R=0.309, p<0.0001), and was significantly 
higher in male when compared to female (median 2.5 vs 
1.8 ng/ml, p=0.007). On the other hand, blood CEA level 
was not affected by tumor location.
These results indicated that serum miR-139-3p level 
was a promising and independent biomarker for CRC 
screening and showed high sensitivity in CRC patients of 
different tumor locations and stages.
DISCUSSION
In this study, we showed that serum miR-139-3p was 
a promising biomarker for screening CRC patients with 
a high AUC (0.9935), sensitivity (96.6%) and specificity 
(97.8). It is quite rare for a single biomarker to achieve 
such good performance in distinguishing cancer patients 
from normal subjects. Our results revealed that there was a 
large difference in 139-3p level between CRC and normal, 
at both tissue and serum levels. MiR-139-3p was expressed 
in adjacent normal mucosa samples of 33 CRC patients, 
whereas loss expression of this miRNA was detected in 
31 of them, and the remaining 2 patients also displayed 
~8-fold reduction of miR-139-3p level in their CRC 
specimens, indicating that miR-139-3p was significantly 
silenced or repressed during CRC development. In line 
with its repression in CRC in comparison to paired non-
tumor tissue, serum miR-139-3p level in CRC patients 
was also significantly lower than that in control subjects, 
with an average of ~64-fold reduction. These results 
consistently demonstrated that miR-139-3p expression 
was significantly repressed at both tissue and serum levels 
of CRC patients, providing an explanation to the high 
performance of this potential biomarker in identifying 
CRC patients. This study demonstrated that serum miR-
139-3p showed higher AUC, sensitivity and specificity 
when compared to other potential biomarker such as 
blood CEA. In addition, serum miR-139-3p showed 
high AUC and sensitivities in both early and late stage 
CRCs and CRCs at proximal and distal locations, thus 
serum miR-139-3p is able to compensate the limitation of 
sigmoidoscopy and FOBT that show lower sensitivity for 
proximal CRC [13] and some blood-based biomarkers, for 
example, blood CEA that show lower sensitivity for early 
stage CRC [14]. In addition, serum miR-139-3p showed 
no correlation with age or gender, whereas in this study 
we showed that blood CEA level was affected by age and 
gender. These results suggested that serum miR-139-3p 
could be an additional screening test for patients in whom 
other conventional screening might show false-negative or 
false-positive results.
One limitation of this study is patients with 
colorectal polyps were not included for comparison. It is 
worth investigating whether serum miR-139-3p level can 
identify this type of patients from normal subjects. If it 
can, this biomarker could help to detect patients with high 
risk of polyps so that they can have their polyps surgically 
resected before it is progressed into cancer, which aids 
in reducing the prevalence of CRC. On the other hand, if 
serum miR-139-3p level in patients with colorectal polyps 
was similar to that of normal subjects, it can still be used 
to identify high-risk CRC patients who require further 
colonoscopy confirmation, so that surgical operation can 
be applied to those showing positive findings as early as 
possible. Hence, further study on the serum level of this 
miRNA in patients with colorectal polyps is warranted to 
determine its potential application.
Notably, certain types of patients might not be 
appropriate for this screening approach, for example, 
patients with adrenocortical carcinoma, bladder 
carcinoma in situ and adrenal pheochromocytomas in 
which dysregulation of miR-139-3p in tissue level has 
been reported [15–17]. Moreover, though miR-139-3p 
repression in CRC was demonstrated in this study and the 
others [18, 19], high miR-139-3p was on the other hand 
associated with liver metastasis in another study [20]. 
Therefore, further studies investigating the serum miR-
139-3p level in patients with diseases mentioned above 
are warranted to improve the precision of this biomarker.
Previously, Kanaan et al reported a panel of plasma 
miRNAs including miR-139-3p and two other miRNAs 
(miR-431 and miR-15b distinguished Stage IV CRC from 
controls with an [AUC = 0.896 (95% CI: 0.78−1.0)] [21]. 
Their study demonstrated a 25-fold change in miR-139-
3p level comparing CRC and control plasma samples, 
whereas our study demonstrated a 64-fold change in 
serum samples comparing CRC and control subjects. 
This greater discrepancy in serum miR-139-3p level 
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provides an explanation to the higher AUC, sensitivity 
and specificity obtained in our study. We surmise two 
factors contributing to such difference. Firstly, Kanaan et 
al’s study examined the level of miR-139-3p in plasma 
whereas we detected its level in serum. Secondly, the 
ethnic background of the sample population in their study 
and our study was different. Both these factors have been 
reported to affect the miRNA level. Wang et al reported 
that the serum samples always showed higher miRNA 
concentrations than plasma and caution must be taken 
when comparing miRNA data generated from different 
sample types [22]. Zhao ZH et al. had revealed the profiles 
of circulating miRNAs in plasma samples from Caucasian 
American women or that from African American with 
early breast cancer were inconsistent, and separate 
case-versus-control comparisons stratified by race were 
necessary [23]. Since this study did not compare miR-139-
3p level between serum and plasma samples, nor among 
samples of different race, we could not conclude their 
effects on miR-139-3p level. However, we believed that 
the diagnostic performance in different sample types and 
ethnic background should also be determined for potential 
miRNA biomarkers in the future.
In line with Balaquer F et al’s study which reported 
miR-622 as one of the most significantly upregulated 
miRNAs in CRC [24], this study showed that miR-622 was 
significantly overexpressed in CRCs and high expression 
associated with lymph node and distant metastases. On 
the other hand, another study showed that miR-622 was 
down-regulated in CRC and miR-622 level was lower 
in metastatic CRCs than in non-metastatic counterparts 
[25]. These contradictions suggest that the role of miR-
622 in CRC is more complicated than expected. Notably, 
though we reported serum miR-622 was more frequently 
detectable in CRC patients than in control subjects, the 
mean level of this serum miRNA was on the other hand 
higher in normal subjects when comparing the control 
and CRC individuals with detectable level of serum 
miR-622. Since this study aimed at investigating the 
diagnostic potential of serum miRNAs for CRC, we did 
not further look into the underlying mechanism of miR-
622 overexpression or repression in CRC. Nevertheless, 
we believed that a comprehensive investigation of the 
regulatory mechanism of miR-622 in CRC could improve 
our knowledge on miRNA biology as such contradictory 
observations have also been reported for other miRNAs 
[26–28].
In conclusion, we demonstrated that the miR-139-3p 
level in both tissue and serum samples was significantly 
lower in CRC patients, and its serum level showed a high 
sensitivity and specificity for CRC diagnosis. Further 
validation can be performed for this serum miRNA or 
in combination with other miRNAs which showed high 
potential for CRC screening to form a detection panel, 
in order to detect the disease of CRC patients as early as 
possible so that their prognosis will be improved.
MATERIALS AND METHODS
Sample size calculation
The sample size required for this diagnostic test 
was calculated using the characteristics represented by 
the sensitivity and specificity of serum miRNA to detect 
CRC. According to our pilot study which included 72 
CRC patients and 48 control subjects, the sensitivity and 
specificity of miR-139-3p were both ~95%. Hence, around 
93 CRC patients and normal subjects will be required to 
obtain the lower limit of the 95% confidence interval of 
both the sensitivity and specificity to be > 85% [29].
Patient tissue and blood samples
The study included 42 paired tumor and adjacent 
non-tumor tissues from CRC patients who had their 
tumor specimens resected at the Department of Surgery, 
Queen Mary Hospital, HKSAR, between the years 
2009 and 2011. All samples were flash-frozen in liquid 
nitrogen, and stored at −80°C until further molecular 
analysis. This study also included pre-operative serum 
sample from 117 CRC patients between 2011 and 2016 
and serum sample from 90 control subjects between 
2013 and 2016 who showed no cancer and colorectal 
polyp in their colonoscopy examination. Serum was 
collected following centrifugation of blood at 400 x g for 
10 min. The supernatant was transferred to new 1.5-ml 
centrifugation tubes and stored at −80°C. Written consent 
was received for all patients whom we recruited. The 
clinicopathological data was obtained from the hospital 
records relating to age, gender, diagnosis, tumor location 
and size, TNM staging, local invasion, differentiation 
and distant metastasis. This study was approved by the 
Institutional Review Board of the hospital.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from tumor tissue and 
adjacent normal mucosa or serum sample (250 μl) using 
mirVana® miRNA isolation Kit (Ambion, Austin, TX) 
according to the manufacturer’s instructions. The RNA 
concentrations were measured using Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA). This total RNA was used to reverse transcribe 
mRNA complementary DNA (cDNA) and miRNAs using 
TaqMan Microarray Assays (Applied Biosystems, Foster 
City, CA). Each reverse transcriptase reaction utilized 10 
ng of total tissue RNA or 3.33 μl total serum RNA, 0.15 
μl dNTP (100 mM total), 1.00 μl Multiscribe RT enzyme 
(50 U/μl), 1.50 μl 10X RT buffer, 0.19 μl RNase Inhibitor 
(20 U/μl) and 3 μl 5X RT primer making a total reaction 
volume to 15 μl with nuclease-free water. TaqMan 
microRNA assay (Applied Biosystems, Foster City, CA) 
were used to relatively quantify and detect the miRNA 
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levels of miR-139-3p, miR-622; U6 and RNU48 were 
utilized as internal controls. The reversely transcribed 
cDNA was diluted 1:20 before the qPCR reaction 
volume was mixed and 1.33 μl was combined with 10 
μl 2X Universal PCR Master Mix (no AmpErase UNG), 
7.67 μl water and 1.0 μl 20X MicroRNA Assay. A total 
volume of 20 μl per reaction was transferred to a 96-well 
MicroAmp plates (Applied Biosystems, Foster City, CA) 
and incubated for 10 min at 95°C, followed by 40 cycles 
at 95°C for 15 sec. then 60°C for 60 sec. All samples were 
run in duplicates. Samples with cycle threshold (Ct) over 
40 were regarded as no expression. The relative miRNA 
level was expressed as −ΔCt, which is calculated by the 
formula: −(Ct of miR-139-3p minus Ct of U6).
Statistical analysis
The comparison of miRNA level between paired-
tumor and non-tumor tissues was done by paired t-test 
or Fisher exact test. The serum miRNA levels of CRC 
patients and control subjects were compared using 
Student’s t-test or Fisher exact test. Associations between 
miRNA expression and clinicopathological features were 
explored using Student’s t-test, Mann–Whitney U test or 
Spearman correlation. All relationships of the relative 
expression of the target miRNA were performed using 
SigmaStat 3.5 (Systat Software Inc., San Jose, CA, USA) 
and P< 0.05 was considered to be statistically significant.
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